The Graft-Versus-Leukemia Effect of Post-transplant Donor Leukocyte Infusion

References

• Bortin M. M., Horowitz M. M., Rimm A. A. Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transpl. 1992; 10: 113
   PubMed Web of Science ®Google Scholar
• Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment, S. J. Burakoff, H. J. Deeg, J. Ferrara, K. Atkinson. Marcel Dekker, Inc., New York, NY 1990
   Google Scholar
• Komgold R. Biology of graft-vs-host disease. Am. J. Ped. Hem. One 1993; 15: 18
   PubMed Web of Science ®Google Scholar
• Vallera D. A., Soderling C. C. B., Carlson G. J., Kersey J. H. Bone marrow transplantation across major histocompatability barriers in mice. II. T cell requirements for engraftment in total lymphoid irradiation-conditioned recipients. Transpl. 1982; 33: 243
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Filipovich A. H., Kersey J. H., . T-cell depletion of donor marrow grafts: Effects on graft-versus-host disease and engraftment. Progress in Bone Marrow Transplantation, R. P. Gale, R. Champlin, et al. Alan R. Liss, New York 1987; 381
   Google Scholar
• Truitt R. L., Shih C. C.-Y., Lefever A. V. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma. Transpl. 1986; 41: 301
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Torok-Storb B., et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transpl. 1988; 3: 445
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Torok-Storb B., et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transpl. 1988; 3: 437
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555
   PubMed Web of Science ®Google Scholar
• Marmont A. M., Horowitz M. M., Gale R. P., Sobocinski K., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Horowitz M. M. Graft-vs-leukemia effects in clinical bone marrow transplantation. Graft-vs-Host Disease, S. J. Burakoff, H. J. Deeg, J. Ferrara, K. Atkinson. Marcel Dekker, New York 1990; 691
   Google Scholar
• Vos O., Weyzen W. W. H. “Killing effect” of injected lymph node cells in homologous radiation chimeras. Transpl. Bull. 1962; 30: 501
   Google Scholar
• Weiden P. L., Storb R., Tsoi M., Graham T. C., et al. Infusion of donor lymphocytes into stable canine radiation chimeras: Implications for mechanism of transplantation tolerance. J. Immunol. 1976; 116: 1212
   PubMed Web of Science ®Google Scholar
• Slavin S., Fuks Z., Kaplan H. S., Strober S. Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation. J. Exp. Med. 1978; 147: 963
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm C., Holler E., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462
   PubMed Web of Science ®Google Scholar
• Giralt S. A., Champlin R. E. Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994; 84: 3603
   PubMed Web of Science ®Google Scholar
• Drobyski W. R., Roth M. S., Thibodeau S. N., Gottschall J. L. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transpl. 1992; 10: 301
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Jiang Y. Z., Schwarer A. P., Hughes T. P., et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379
   PubMed Web of Science ®Google Scholar
• Frassoni F., Fagioli F., Sessarego M., Gualandi F., et al. The effect of donor leukocyte infusion in patients with leukemia following bone marrow transplantation. Exp. Hematol., (Abstract) 1992; 20: 712
   Web of Science ®Google Scholar
• Drobyski W. D., Keever C. A., Roth M. S. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed CML after allogeneic BMT: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310
   PubMed Web of Science ®Google Scholar
• Szer J., Grigg A. P., Phillips G. L., Sheridan W. P. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transpl. 1993; 11: 109
   PubMed Web of Science ®Google Scholar
• Bar B. M. A. M., Schattenberg A., Mensink E. J. B. M., Kessel A. G. V., et al. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J. Clin. Oncol. 1993; 11: 513
   PubMed Web of Science ®Google Scholar
• Hertenstein B., Wiesneth M., Novotny J., Bunjes D., et al. Interferon-α and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transpl. 1993; 56: 1114
   PubMed Web of Science ®Google Scholar
• Helg C., Roux E., Beris P., Cabrol C., et al. Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transpl. 1993; 12: 125
   PubMed Web of Science ®Google Scholar
• Leber B., Walker I. R., Rodriguez A., McBride J. A., et al. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transpl. 1993; 12: 405
   PubMed Web of Science ®Google Scholar
• Porter D. L., Roth M. S., McGarigle C., Ferrara J. L. M., Antin J. H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 1994; 330: 100
   PubMed Web of Science ®Google Scholar
• Van Rhee F., Cullis J. O., Spencer A., Cross N. C. P., et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377
   PubMed Web of Science ®Google Scholar
• Ferster A., Bujan W., Mouraux T., Devalck C., et al. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transpl. 1994; 14: 331
   PubMed Web of Science ®Google Scholar
• Mehta J., Powles R., Singhal S., Taint D., et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transpl. 1995; 16: 133
   PubMed Web of Science ®Google Scholar
• Bernasconi P., Alessandrino E. P., Caldera D., Bonfichi M., et al. Intensive chemotherapy followed by donor PBSC in ANLL relapsed after allogeneic BMT. Bone Marrow Transpl. 1995; 15: 643
   PubMed Web of Science ®Google Scholar
• Mackinnon S., Papadopoulos E. B., Carabasi M. H., Reich L., et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response?. Bone Marrow Transpl. 1995; 15: 591
   PubMed Web of Science ®Google Scholar
• Mackinnon S., Papadopoulos E. B., Carabasi M. H., Reich L., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Schattenberg A., Goldman J. M., Hertenstein B., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041
   PubMed Web of Science ®Google Scholar
• Jiang Y. Z., Cullis J. O., Kanfer E. J., Goldman J. M., et al. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transpl. 1993; 11: 133
   PubMed Web of Science ®Google Scholar
• Bunjes D., Theobald M., Hertenstein B., Wiesneth M., et al. Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transpl. 1995; 15: 713
   PubMed Web of Science ®Google Scholar
• Papadopoulos E. B., Ladanyl M., Emanuel D., Castro-Malaspina H., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J. Med. 1994; 330: 1185
   PubMed Web of Science ®Google Scholar
• Hromas R., Cornetta K., Srour E. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. New Engl J. Med. 1994; 330: 1689
   Google Scholar
• Johnson B. D., Drobyski W. R., Truitt R. L. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transpl. 1993; 11: 329
   PubMed Web of Science ®Google Scholar
• Johnson B. D., Truitt R. L. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302
   PubMed Web of Science ®Google Scholar
• Ferrara J. L. Advances in GVHD: Novel lymphocyte subsets and cytokine dysregulation. Bone Marrow Transpl. 1992; 10(S1)10
   PubMedGoogle Scholar
• Antin J., Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964
   PubMed Web of Science ®Google Scholar
• Ferrara J., Abhyankar S., Gilliland D. Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1. Transpl. Proc. 1993; 25: 1216
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Impact of pretransplant conditioning and donor T cells on chimerism, graft-vs-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T cells to graft-vs-host disease and graft-vs-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transpl. 1991; 8: 51
   PubMed Web of Science ®Google Scholar
• Antin J. H. Graft-versus-leukemia: No longer an epiphenomenon. Blood 1993; 82: 2273
   PubMed Web of Science ®Google Scholar
• Weiss L., Reich S., Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest. 1992; 10: 19
   PubMed Web of Science ®Google Scholar
• Sykes M., Chester C. H., Sachs D. H. Protection from graft-versus-host disease in fully allogeneic chimeras by prior administration of T cell-depleted syngeneic bone marrow. Transpl. 1988; 46: 327
   PubMed Web of Science ®Google Scholar
• Xun C. Q., Thompson J. S., Jennings C. D., Brown S. A., et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360
   PubMed Web of Science ®Google Scholar
• Frankel W. N., Rudy C., Coffin J. M., Huber B. T. Linkage of Mls genes to endogenous mammary tumour viruses of inbred mice. Nature 1991; 349: 526
   PubMed Web of Science ®Google Scholar
• Macdonald H. R., Schneider R., Lees R. K., Howe R. C., et al. T cell receptor Vβ use predicts reactivity and tolerance to Mls a-encoded antigens. Nature 1988; 332: 40
   PubMed Web of Science ®Google Scholar
• Alters S. E., Shizuru J. A., Ackerman J., Grossman D., et al. Anti-CD4 mediates clonal anergy during transplantation tolerance induction. J. Exp. Med. 1991; 173: 491
   PubMed Web of Science ®Google Scholar
• Desilva D. R., Urdahl K. B., Jenkins M. K. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol 1991; 147: 3261
   PubMed Web of Science ®Google Scholar
• Pechhold K., Pohl T., Kabelitz D. Rapid quantification of lymphocyte subsets in heterogeneous cell populations by flow cytometry. Cytometry 1994; 16: 152
   PubMedGoogle Scholar
• Kabelitz D., Oberg H.-H., Pohl T., Pechhold K. Antigen-induced death of mature lymphocytes: Analysis by flow cytometry. Immunol. Rev. 1994; 142: 157
   PubMed Web of Science ®Google Scholar
• Oseroff A., Okada S., Strober S. Natural Suppressor (NS) Cells Found in the Spleen of Neonatal Mice and Adult Mice Given Total Lymphoid Irradiation (TLI) Express the Null Surface Phenotype. J. Immunol. 1984; 132: 101
   PubMed Web of Science ®Google Scholar
• Maier T., Holda J. H., Claman H. N. Graft-Vs-Host Reactions (GVHR) Across Minor Murine Histocompatability Barriers. II. Development of Natural Suppressor Cell Activity. J. Immunol. 1985; 135: 1644
   PubMed Web of Science ®Google Scholar
• Sadelain M. W. J., Green D. R., Wegmann T. G. Host Natural Suppressor Activity Regulates Hemopoietic Engraftment Kinetics in Antibody-Conditioned Recipient Mice. J. Immunol. 1990; 144: 1729
   PubMed Web of Science ®Google Scholar
• Saffran D. C., Singhal S. K. Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities. Cell. Immunol. 1990; 128: 301
   PubMed Web of Science ®Google Scholar
• Sykes M., Sharabi Y., Sachs D. H. Natural Suppressor Cells in Spleens of Irradiated, Bone Marrow-Reconstituted Mice and Normal Bone Marrow: Lack of SCA-1 Expression and Enrichment by Depletion of MAC 1-Positive Cells. Cell. Immunol. 1990; 127: 260
   PubMed Web of Science ®Google Scholar
• Angulo I., Rodriguez R., Garcia B., Medina M., et al. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. J. Immunol 1995; 155: 15
   PubMed Web of Science ®Google Scholar
• Johnson B. D., Truitt R. L. Selective depletion of donor NK cells in vivo decreases graft-vs-host disease without the loss of graft-vs-leukemia reactivity after MHC-matched bone marrow transplantation. Transpl. 1992; 54: 104
   PubMed Web of Science ®Google Scholar
• Johnson B. D., McCabe C., Hanke C. A., Truitt R. L. Use of anti-CD3+ F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J. Immunol 1995; 154: 5542
   PubMed Web of Science ®Google Scholar
• Korngold R., Leighton C., Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transpl. 1994; 58: 278
   PubMed Web of Science ®Google Scholar
• Sykes M., Harty M. W., Szot G. L., Pearson S. A. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560
   PubMed Web of Science ®Google Scholar
• Bonini C., Verzeletti S., Servida P., Rossini S., et al. Transfer of the HSV-TK gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo-BMT. Blood 1994; 84(S1)110a
   Google Scholar